已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression

医学 肝细胞癌 免疫疗法 肿瘤科 内科学 外科 癌症
作者
Tsung‐Hao Liu,San‐Chi Chen,Kun‐Ming Rau,Li‐Chun Lu,Po‐Ting Lin,Yung‐Yeh Su,Wei Teng,Shiue‐Wei Lai,Ren‐Hua Yeh,Tsui-Mai Kao,Pei‐Chang Lee,Chi-Jung Wu,Chien‐Hung Chen,Chih‐Hung Hsu,Shi‐Ming Lin,Yi‐Hsiang Huang,Li‐Tzong Chen,Ann‐Lii Cheng,Ying‐Chun Shen
出处
期刊:Liver cancer [Karger Publishers]
卷期号:13 (5): 509-521
标识
DOI:10.1159/000536549
摘要

Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods: Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial response (PR) or stable disease (SD) per RECIST 1.1 for more than 8 months after initiation of immunotherapy. Oligoprogression and polyprogression were defined as progression at ≤3 and >3 lesions, respectively. Results: A total of 91 durable responders (63 PR and 28 SD) were identified. The majority had chronic viral hepatitis (n = 69, 75.8%). Forty-seven (51.6%) and 44 (48.4%) patients received the index immunotherapy as first-line and second- or beyond-line therapy, respectively. Fifty-four (59.3%) patients subsequently developed progression, with a predominant pattern of oligoprogression (66.7%). The median overall survival (OS) was 46.2 months (95% CI: 34.1–58.3). For patients with subsequent progression, employment of locoregional therapy (LRT) for progression was associated with prolonged OS (univariate analysis: hazard ratio [HR] 0.397, p = 0.009; multivariate analysis: HR 0.363, p = 0.050). Patients with oligoprogression who received LRT showed longer median OS than those who did not (48.4 vs. 20.5 months, p < 0.001). In contrast, the median OS of patients with polyprogression who received LRT was not different from those without LRT (27.7 vs. 25.5 months, p = 0.794). Conclusion: Approximately 60% of the post-immunotherapy durable responders of HCC subsequently develop progression. Proactive LRT may further rescue patients who develop subsequent oligoprogression. Prospective studies are mandatory to clarify the proper management of durable responders with subsequent progression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas应助飞奔小子采纳,获得10
刚刚
cookerlin发布了新的文献求助10
2秒前
呼呼完成签到,获得积分10
2秒前
xinbowey发布了新的文献求助10
3秒前
铮铮铁骨发布了新的文献求助10
3秒前
袁翰将军完成签到 ,获得积分10
4秒前
5秒前
科研通AI5应助科研通管家采纳,获得10
6秒前
科研通AI5应助科研通管家采纳,获得30
6秒前
隐形曼青应助科研通管家采纳,获得10
6秒前
lcj1014发布了新的文献求助10
6秒前
7秒前
8秒前
8秒前
9秒前
啊盘发布了新的文献求助10
10秒前
飞奔小子发布了新的文献求助10
13秒前
HL发布了新的文献求助10
13秒前
xinbowey完成签到,获得积分10
14秒前
乐天派完成签到,获得积分10
15秒前
小羊完成签到 ,获得积分10
16秒前
小六子完成签到,获得积分10
17秒前
大个应助晨昏采纳,获得10
18秒前
正直红酒完成签到 ,获得积分10
19秒前
20秒前
Xxx完成签到 ,获得积分10
21秒前
复杂静竹发布了新的文献求助10
24秒前
阿米完成签到 ,获得积分10
26秒前
李亮发布了新的文献求助10
29秒前
于平川春野完成签到 ,获得积分10
29秒前
LLLaiwrite应助CQ采纳,获得10
30秒前
cmxing完成签到,获得积分10
30秒前
Kolalone发布了新的文献求助10
31秒前
FashionBoy应助liamddd采纳,获得10
33秒前
浮游应助JY采纳,获得10
34秒前
彭进水完成签到,获得积分10
35秒前
科研通AI6应助HL采纳,获得10
35秒前
复杂静竹完成签到,获得积分10
37秒前
霜降完成签到 ,获得积分10
39秒前
40秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
International Encyclopedia of Business Management 1000
Encyclopedia of Materials: Plastics and Polymers 1000
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Hidden Generalizations Phonological Opacity in Optimality Theory 1000
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4934784
求助须知:如何正确求助?哪些是违规求助? 4202490
关于积分的说明 13057669
捐赠科研通 3976951
什么是DOI,文献DOI怎么找? 2179303
邀请新用户注册赠送积分活动 1195452
关于科研通互助平台的介绍 1106840